COVID-19 in lung transplant recipients: A case series from Milan, Italy

Letizia Corinna Morlacchi, Valeria Rossetti, Lorenzo Gigli, Francesco Amati, Lorenzo Rosso, Stefano Aliberti, Mario Nosotti, Francesco Blasi, Letizia Corinna Morlacchi, Valeria Rossetti, Lorenzo Gigli, Francesco Amati, Lorenzo Rosso, Stefano Aliberti, Mario Nosotti, Francesco Blasi

Abstract

Limited data are currently available regarding the course of COVID-19 in lung and solid organ transplant recipients. We hereby present four cases of SARS-CoV-2 pneumonia in lung transplant recipients from our center, set in Milan, Italy. We reduced immunosuppressive regimen in all these patients, typically holding the antiproliferative agent and augmenting steroids; everybody received hydroxychloroquine, initial empiric antibiotic treatment with piperacillin/tazobactam, and high-dose low molecular weight heparin. Clinical course seemed favorable in three of our patients, but one of them deteriorated after 10 days of hospitalization, probably due to an acute form of graft dysfunction triggered both by COVID-19 and a nosocomial bacterial infection, and eventually died. Although short-term prognosis could be considered benign in the majority of our patients, we should carefully monitor these individuals in order to detect early sign of clinical deterioration and graft dysfunction in the next few months.

© 2020 Wiley Periodicals LLC.

References

REFERENCES

    1. Saima A, Danziger-Izakov L, Luong ML, et al.Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic.
    1. Kaltsas A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. Curr Opin Infect Dis. 2012 Aug;25(4):423-430.
    1. Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs. nonimmunocompromised hosts. Clin Infect Dis. 2014;58(2):214-224.
    1. Aslam S, Mehra MR, COVID-19: yet another coronavirus challenge in transplantation. J Heart and Lung Transpl. 2020;39(5):408-409.
    1. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584-591.
    1. Abadja F, Atemkeng S, Alamartine E, et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation. 2011 Aug 27;92(4):396-403.
    1. Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or infection-beta1b improves outcome of MERS-CoV infection in a non human primate model of common marmoset. J Infect Dis. 2015;212(12):1904-1913.
    1. Carbajo-Lozoya J, Müller MA, Kallies S, et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165(1):112-117.
    1. Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancer. 2020;14:1022.
    1. Romanelli A, Mascolo S. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical analysis. Am J Transpl. 2020;3.
    1. Marcus R, MohanSumit CJ, HusainSyed A, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation. 2020.
    1. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97(6):1083-1088.
    1. Montagud-Marrahi E, Cofan F, Torregrosa JV, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single centre cohort of kidney recipients. Am J Transplant. 2020.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
    1. Mousavi S, Moradi M, Khorshidahmad T, et al. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015;2015:1-14.
    1. Thachil J. The Versatile Heparin in COVID-19. J Thromb Haemost. 2020;18(5):1020-1022.
    1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with Severe Covid-19. N Engl J Med. 2020.382(19):1787-1799.
    1. Wampler Muskardin TL IV anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID19. ACR Open. Rheumatol. 2020. (in press).
    1. Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther. 2020;14(2):73-76.
    1. Peghin M, Los-Arcos I, Hirsch HH, et al. Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction. Clin Infect Dis. 2019;69(7):1192-1197.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner